Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNA tattoo vaccination with HPV16 E6/E7 DNA vaccines in HPV16-positive usual vulvar intraepithelial neoplasia
NL-OMON29038Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2017
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sig-HELP-E6SH-kdel and sig-HELP-E7SH-kdel in vulvar intraepithelial neoplasia (VIN), sponsored by Netherlands Cancer Institute. Primary endpoint: Systemic HPV-specific immune response. Started Jan 2017; status: recruiting.
02
Drugs
sig-HELP-E6SH-kdelsig-HELP-E7SH-kdel
03
Conditions
vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on NL-OMON29038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29038.